Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran
WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) – Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus” or the "Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B ("cHBV”).